Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.02 USD | +0.59% | -7.54% | +81.29% |
14/05 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
13/05 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+81.29% | 284M | |
+68.95% | 62.86B | |
-0.96% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+14.12% | 26.46B | |
-21.79% | 18.9B | |
+4.24% | 12.67B | |
+24.02% | 12.27B | |
+28.51% | 12.07B |
- Stock Market
- Equities
- INO Stock
- News Inovio Pharmaceuticals, Inc.
- Inovio Pharma Says EMA Panel Backed Approval of Orphan Designation for Respiratory Disease Drug Candidate